Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Notebook: Pricing Mistrust Needs Open Debate; Rasi Nears EMA Return; Market Turmoil Affects IPOs

Executive Summary

The EU’s Health Commissioner called for an open debate on pharmaceutical pricing with industry, while Guido Rasi prepares for part two of helming the European Medicines Agency and German big pharmas Bayer and Merck KGaA completed business restructuring. More developments in this month's column.

You may also be interested in...



Acacia's Euronext Listing To Help Target Unmet US PONV Market

Acacia Pharma’s long-term aim, once its go-it-alone US strategy is in hand, is to turn its attention to ex-US partnering possibilities for its lead product for post-operative nausea and vomiting. It will also develop a Phase II candidate for chemotherapy-induced nausea and vomiting.

European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes

Once-in-a-decade leadership changes stack up in Europe’s big pharma companies as the region aims for quicker and more certain drug development, although following a recent fatality an expert committee is advising caution during dose-escalation in Phase I studies.

European Notebook: Clinical Trial Fatality; Affordable Medicines Debate; Physician Payment Disclosure

One death and five healthy volunteers hospitalized in a Phase I study in France; EU Council looks set to debate patient access to medicines; and the two Mercks set to continue litigation in Europe and the US over use of the Merck word, straining their 60-year-old agreement. Generics/biosimilar trade group adopts physician payment disclosure policy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel